SynthesisJournal of clinical laboratory analysis2022
COVID-19 in HIV-positive patients: A systematic review of case reports and case series.
Synthesis in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Clinical symptoms, diagnosis, treatment, and outcome of COVID-19-associated encephalitis: A systematic review of case reports and case series.Journal of clinical laboratory analysis · 2022Pooled it
- Clinical manifestations, treatment options, and comorbidities in COVID-19 relapse patients: A systematic review.Journal of clinical laboratory analysis · 2022Pooled it
- COVID-19 in HIV-positive patients: A systematic review of case reports and case series.Journal of clinical laboratory analysis · 2022Pooled it
- The Interplay of HIV and Long COVID in Sub-Saharan Africa: Mechanisms of Endothelial Dysfunction.Current cardiology reports · 2024Review
- Review
- Update on Central Nervous System Effects of the Intersection of HIV-1 and SARS-CoV-2.Current HIV/AIDS reports · 2023Review
- Phenylalanine metabolism and tetrahydrobiopterin bio-availability in COVID-19 and HIV.Heliyon · 2023Article
- Review
- HIV-positive patients diagnosed with COVID-19 in Central and Eastern European Countries.Journal of clinical laboratory analysis · 2022Article
- SARS-CoV-2 and HIV: Impact on Pulmonary Epithelial Cells.Life (Basel, Switzerland) · 2022Article
- Clinical Manifestations, Imaging Procedures and Laboratory Parameters among Hospitalized Patients with COVID-19 in Ilam Province, Western Iran.Ethiopian journal of health sciences · 2022Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionCoronavirus disease 2019 (COVID-19) and acquired immune deficiency syndrome (AIDS) are two viral diseases for which there are currently no definitive treatments. Nowadays, because of the health system's focus on the COVID-19 epidemic, the control of human immunodeficiency virus (HIV) has received less attention. In this review, we will discuss the characteristics of COVID-19 in HIV-positive patients. MATERIAL AND
methodsUsing the PRISMA guideline, the databases of Scopus, PubMed, and Web of Science were searched systematically from January 1, 2019 to February 24, 2021. The following keywords were used: "Human Immunodeficiency Virus," "acquired immune deficiency syndrome," "HIV," "AIDS," "COVID-19," "severe acute respiratory syndrome coronavirus 2," "novel coronavirus," "SARS-CoV-2," "nCoV disease," "SARS2," and "2019-nCoV disease."
resultsTwenty-one percent of studies were conducted in the USA (n = 13), 16% in China (n = 10), and 13% in Italy (n = 8), respectively. The majority of the patients were men (74.3%). Tenofovir disoproxil fumarate was used in 47.4% of patients, emtricitabine in 58.4%, and lamivudine in 34.8% to treat HIV. Symptoms of HIV patients with COVID-19 included coughing (81.3%), fever (62.8%), and dyspnea (60%). Hydroxychloroquine (39.34%) and azithromycin (36.58%) were the common treatment options for COVID-19. The total death rate in HIV-positive patients with COVID-19 was about 9%.
conclusionIn the current systematic review, we demonstrated that HIV-positive patients co-infected with COVID-19 have high comorbidity of hypertension and diabetes mellitus. HIV/COVID-19 co-infection might have negatively influenced the HIV treatment and diagnosis, which indicates the need to regularly screen HIV patients in the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.